89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a pilot study for evaluation of 89Zr-bevacizumab PET imaging as predictive biomarker
during treatment with everolimus in patients with neuroendocrine tumors.
Patients with progressive disease during the last year will receive treatment with everolimus
10 mg/day orally and 89Zr-bevacizumab PET imaging will be performed before start of treatment
and after 2 and 12 weeks of treatment in the first three patients. If the scan after 2 weeks
of treatment is already informative further patients will not undergo a scan at 12 weeks. A
scan is considered already informative if both scans show at least 30% decrease in uptake in
case of response, or at least 30% increase in uptake in case of disease progression.
Four days before the scan patients will be injected intravenously 37 MBq, protein dose 5 mg
89Zr-bevacizumab. At day 1, day 15 and day 99, PET images will be made for visualization and
quantification of VEGF in the tumor lesions and blood will be drawn for determination of
angiogenesis and mTOR pathway related biomarkers.